Bayer Recalls Liquid Leukine For Adverse Effects

Law360, New York (January 25, 2008, 12:00 AM EST) -- Bayer HealthCare announced Wednesday that it would withdraw the current liquid formulation of Leukine from the supply system in the United States, saying it had received an increase in reports of side effects such as fainting.

The company, having consulted with the U.S. Food and Drug Administration, sent a letter to health care professionals on Wednesday asking them to stop using the liquid medication and return any unused vials.

Leukine, a growth factor, enhances immune cell function and fights infections and disease in patients with acute...
To view the full article, register now.